Stories about: Gro
- +
Gro for Tissue Therapies 09/07/2008 16:52:49
Tissue Therapies to commence human VitroGro trials locally - +
Blobology and proteins' little helpers 13/02/2008 12:19:19
One of the world's leading structural biologists, Helen Saibil, is bringing her knowledge -- and some spectacular images -- of molecular chaperones to the Lorne Protein conference. - +
Genetic links illuminate bee social life 13/03/2007 09:41:22
How social life evolved from solitary ancestral lifestyles has been an enduring mystery for years, and now scientists are one step closer to unravelling its genetic underpinnings. - +
GroPep boosts half-year profit by 80 pct 15/02/2006 10:57:49
Adelaide-based GroPep (ASX:GRO) has increased its profit more than 80 per cent after tax to AUD$1.55 million in the half-year to December 31 2005, compared with $850,000 in the previous corresponding period. - +
GroPep goes into phase I infertility trial 10/01/2006 13:41:12
GroPep (ASX:GRO) has begun to recruit healthy women volunteers into a phase I trial of its infertility drug PV903, targeted to treat recurrent miscarriages caused by an abnormal immune response to the foetus. - +
GroPep completes final malaria vaccine milestone 19/12/2005 13:07:44
Adelaide-based biotech GroPep (ASX:GRO) has completed the manufacture of two vaccine antigens for the Bill and Melinda Gates Foundation-funded Malaria Vaccine Initiative (MVI). - +
GroPep changes track from psoriasis drug to asthma 14/12/2005 15:00:28
Following poor efficacy in preclinical testing of its T-cell peptide drug candidate in psoriasis models, Adelaide biopharma GroPep (ASX:GRO) will undertake a market feasibility assessment for use of the drug in asthma. - +
GroPep reports double profits 22/08/2005 14:27:59
Adelaide-based GroPep (ASX:GRO) has recorded pre-tax profit of AUD$3.1 million for the year ending 30 June 2005, an increase of more than 200 per cent over the $1 million reported last year. - +
TGR nets $3m in venture funding 17/08/2005 14:00:50
Unlisted Adelaide-based firm TGR Biosciences has attracted up to AUD$3 million funding from venture capital firm Nanyang Ventures to further clinical development of its treatment for oral mucositis, a debilitating side-effect of cancer treatments. - +
CSL deal boosts GroPep profits 27/07/2005 14:51:13
Adelaide-based GroPep's (ASX:GRO) net profit after tax for the 2004-2005 financial year has been boosted by a one-off tax benefit of AUD$3.4 million, and is now expected to be approximately $6.4 million compared with a previous estimate of $3 million. - +
GroPep clarifies its recurrent miscarriage project to the market 14/07/2005 13:24:20
Media speculation has forced Adelaide-based GroPep (ASX:GRO) to clarify its position on ethics committee approval for a clinical study of an infertility drug.
Additional Resources
Newsletter Subscription
Australian Life Scientist Member Login
Kingston Technology Launches HyperX T1 Series Memory 2008-11-19 11:00:00+11
Erase your discs with Lite-On SmartErase 2008-11-12 14:00:00+11
Antarctica NZ to Optimise Satellite Communications over the WAN with Expand Networks 2008-11-11 08:22:00+11
Kingston Technology Launches HyperX DDR3 2GHz Triple-Channel Memory in Support of Intel Core i7, X58 Platforms 2008-11-06 16:40:00+11
WD TV™ HD Media Player brings Digital Media Collections to the Big Screen 2008-11-05 11:00:00+11
Sponsored Links


